Pancreatic Cancer Research

ResearcherUniversity of California San DiegoNo recent work listed

Hitendra Patel

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.

Their work

Papers
2
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2019: 2 trials · 2020: none · 2021: 2 papers

Papers 2

  1. Neoadjuvant Checkpoint Blockade in Lynch Syndrome-Related Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001742↗
  2. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. Co-author DOI 10.1172/jci.insight.150453↗

Trials 2

  1. High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer Principal investigator NCT03697239↗
  2. Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Principal investigator NCT03697564↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew M. Lowy · 1 shared paper, 1 shared trial, 2019–2021 · strength 0.49
  2. Betzaira G. Childers · 1 shared paper, 2021 · strength 0.19
  3. Shumei Kato · 1 shared paper, 2021 · strength 0.15
  4. Razelle Kurzrock MD · 1 shared paper, 2021 · strength 0.15
  5. Gregory P. Botta · 1 shared paper, 2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.